Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis

Back to Search
Print
Bookmark Trial

NCT00762463

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Guangzhou, Guangdong, 510630, China
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ankylosing Spondylitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Meet the 1984 Modified New York Criteria for Classification of Ankylosing Spondylitis

- With axial involvement

- Without peripheral joint involvement (synovitis) at the time of study entry, (excluding involvement of the hips, knees and shoulders)

- Need for daily treatment with NSAIDs during the previous 30 days before study entry

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Known inflammatory enteropathy (eg, ulcerative colitis, Crohn's disease, etc)


- Presence of extra-articular manifestations (eg, uveitis, endocarditis, etc.)


- Known vertebral compression


- Need for a corset during the study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Ankylosing SpondylitisA Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis
NCT00811499
  1. Los Angeles, California
  2. Chicago, Illinois
  3. Omaha, Nebraska
  4. Oklahoma City, Oklahoma
  5. Portland, Oregon
  6. Charleston, South Carolina
  7. Spokane, Washington
  8. Edmonton, Alberta
  9. Winnipeg, Manitoba
  10. Mississauga, Ontario
  11. Trois-Rivieres, Quebec
  12. Saskatoon, Saskatchewan
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ankylosing SpondylitisTo Investigate Genetic Factors Associated With the Response to Anti-TNF Therapy in Patients With Early AS
NCT02311842
  1. Guangzhou, Guangdong
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ankylosing SpondylitisStudy To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
NCT04507763
  1. Baghdad,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ankylosing SpondylitisA Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis
NCT02528201
  1. Bekkestua,
  2. Bergen,
  3. Bergen,
  4. Bodø,
  5. Bærum Postterminal,
  6. Drammen,
  7. Gamle Fredrikstad,
  8. Hamar,
  9. Harstad,
  10. Haugesund,
  11. Horten,
  12. Jessheim,
  13. Kongsvinger,
  14. Kristiansand,
  15. Kristiansand,
  16. Lena,
  17. Levanger,
  18. Lillehammer,
  19. Mo I Rana,
  20. Oslo,
  21. Oslo,
  22. Oslo,
  23. Skien,
  24. Tiller,
  25. Tromsø,
  26. Trondheim,
  27. Ålesund,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis
Official Title  ICMJE A 6-Week, Randomized, Double-Blind, Parallel-Group Study To Evaluate The Symptomatic Effects And Safety Of Celecoxib 200mg QD Compared To Diclofenac 75mg SR QD In Chinese Patients With Ankylosing Spondylitis, With 6-Week Extension Phase Treatment On Celecoxib 400 Mg QD Or Maintaining Double-Blind Phase Therapy
Brief Summary This is a local, multicenter, randomized, active comparator, double-blind, parallel group study with extension will be conducted to evaluate the efficacy and safety of celecoxib versus diclofenac SR in the treatment of Chinese patients with Ankylosing Spondylitis (AS).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Ankylosing Spondylitis
Intervention  ICMJE
  • Drug: Celecoxib
    capsule, 200 mg QD, 6-12 weeks
  • Drug: Diclofenac SR
    tablet, 75 mg QD,6-12 weeks
Study Arms  ICMJE
  • Experimental: Celecoxib 200 mg QD
    Intervention: Drug: Celecoxib
  • Active Comparator: Diclofenac SR 75 mg QD
    Intervention: Drug: Diclofenac SR
Publications * Huang F, Gu J, Liu Y, Zhu P, Zheng Y, Fu J, Pan S, Le S. Efficacy and safety of celecoxib in chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatment. Curr Ther Res Clin Exp. 2014 Dec 5;76:126-33. doi: 10.1016/j.curtheres.2014.08.002. eCollection 2014 Dec.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 24, 2009)		240
Original Estimated Enrollment  ICMJE
 (submitted: September 29, 2008)		420
Actual Study Completion Date  ICMJE August 2010
Actual Primary Completion Date June 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Meet the 1984 Modified New York Criteria for Classification of Ankylosing Spondylitis
  • With axial involvement
  • Without peripheral joint involvement (synovitis) at the time of study entry, (excluding involvement of the hips, knees and shoulders)
  • Need for daily treatment with NSAIDs during the previous 30 days before study entry

Exclusion Criteria:

  • Known inflammatory enteropathy (eg, ulcerative colitis, Crohn's disease, etc)
  • Presence of extra-articular manifestations (eg, uveitis, endocarditis, etc.)
  • Known vertebral compression
  • Need for a corset during the study
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00762463
Other Study ID Numbers  ICMJE A3191348
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP